

혈전용해 효과 개선을 위한 약제 투여 방법의 중요성

- TIMIKO 다기관 연구에서 본 Urokinase 효과 -

노 영 무

How Important is the Mode of Thrombolytic Agents Administration for Optimal Thrombolysis?

- Comments on the Results of Double Bolus Urokinase Regimen in Thrombolysis in Myocardial Infarction in Korea (TIMIKO) Multicenter Trial -

Young Moo Ro, M.D.

Cardiology Division, Korea University Hospital, College of Medicine, Korea University, Seoul, Korea

가 . 가 (TIMI 가
) 60
80% PTCA
가
PTCA가 PTCA
PTCA PTCA
가 가
가
p1664 참조
가

PTCA 가 PTCA t-PA do-
가 PTCA ule bolus urokinase
가 PTCA 1)

새로운 혈전용해제의 개발의 한계

: , 136 - 075 5가

: (02) 920 - 5445 · : (02) 927 - 1478
E - mail : hhansin@unitel.co.kr

가

reteplase(rTPA), lanoteplase, TNK - tPA
human t - PA staphylokinase

TIMIKO 가 TIMIKO
urokinase

t - PA

가

double bolus

90

. Urokinase

2)3)

가

가

가

가

50%

t - PA

150

(18)

30

150

double bolus

50kg

혈전용해제 투여방법의 개선

가

가

150

kg

2

가

tPA

t - PA

accelerated UK

70%

double

front - loaded t - PA

acceler -

bolus

ated t - PA

TIMI

80%

Gubla

가

new accelerated rtPA

20

urokinase

mg

bolus

80mg

60

urokinase

2

가

90

81.1%

TIMI

가

accelerated t - PA

TIMIKO 연구의 의의

TIMI

50 60%

TIMIKO

29

4)

urokinase

가

가

Urokinase

200

60 70%

200 300

가
가
가 Urokinase가
가
(American Journal of Cardiology)
5) 가
가
urokinase double bolus
accelerated t - PA
Neuhaus 6) urokinase rt -
PA 가
가
가

REFERENCES

- 1) TIMIKO (Thrombolysis in Myocardial Infarction in Korea). *A Randomized Comparison of Double Urokinase versus Front-Loaded Alteplase Regimen for Acute Myocardial Infarction*. *Korean Circ J* 1998;1664:1669.
- 2) Cannon CP, McCabe CH, Gibson M, Ghali M, Sequeira RF, McKendall GR, et al. *TNK-Tissue Plasminogen Activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial*. *Circulation* 1997;95:351.
- 3) Ogata N, Ogawa H, Ogata Y, Numata Y, Morigami Y, Suefugi H, et al. *Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction*. *Jpn Circ J* 1998; 62:801.
- 4) Gubla DC, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, et al. *Sixty-minute Alteplase Protocol: A new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction*. *J Am Coll Cardiol* 1997;30:1611.
- 5) Park SJ. *Comparison of double bolus urokinase versus front-loaded Alteplase regimen for acute myocardial infarction*. *Am J Cardiol* 1998;82:811.
- 6) Neuhaus K-L, Tebbe U, Gottwik M, Weber MAJ, Feuerer W, Niederer W, et al. *Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: Results of the German Activator Urokinase Study (GAUS)*. *J Am Coll Cardiol* 1988;12:581.